|
|
|
|
|
|
|
|
|
|
Autologous CAR T-cell therapy offers enormous potential, but patient-specific manufacturing presents challenges in turnaround time, quality, scalability, and technology transfer. In this Cell & Gene Live on Oct. 15, 2026 at 11 AM ET, Mayo Clinic experts will share practical insights on overcoming production bottlenecks, strengthening quality-focused processes, partnering with CDMOs, evaluating alternative platforms, and making early CMC decisions that support clinical execution and commercial readiness. Registration is free.
|
|
|
|
|
|
|
|
By PharmaSource
|
Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.
|
|
|
|
|
|
|
|
|
|
|
|
Vial Containment Systems For Gene Therapies
|
|
E-Book | By Margaret A. Craig, Rui Li, Ph.D., et al., West Pharmaceutical Services, Inc.
|
Tests show cyclic olefin polymer vials match or exceed borosilicate glass in vector recovery, closure integrity, and particle safety at ultra-low storage temperatures.
|
|
|
|
|
|
A Model To Produce CAR-T, Anywhere
|
|
Application Note | Vector BioMed
|
Standardized point-of-care manufacturing overcomes cell therapy access, cost, and supply challenges, enabling regional centers to efficiently deliver high-quality treatments.
|
|
|
|
|
|
Put Your AAV On The Fast-Track To The Clinic
|
|
White Paper | Catalent
|
Review an innovative method to fast-tracking AAVs through a platform approach that easily scales as the project progresses to late-stage GMP production and to market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|
